Astal Laboratories schedules board meeting to approve FY26 results
- Astal Laboratories schedules board meeting for September 4, 2026
- Agenda includes approval of financial results for FY ended March 31, 2026
- Board to approve notice and logistics for 33rd Annual General Meeting
- Appointment of scrutinizer for AGM voting is also on the agenda

*this image is generated using AI for illustrative purposes only.
Astal Laboratories Limited has scheduled a board meeting for September 4, 2026, to consider and approve the financial results for the fiscal year ended March 31, 2026.
The company informed the Bombay Stock Exchange on August 31, 2026, that the meeting will also address the notice for its 33rd Annual General Meeting. The board intends to fix the day, date, time, and venue for the upcoming AGM during this session.
Agenda Details
The board meeting agenda includes several key corporate governance items alongside the financial approvals. The directors will approve the Board Report along with all necessary annexures for FY26.
Additionally, the board plans to appoint a scrutinizer to oversee voting procedures during the AGM, including remote e-voting processes. The meeting will be held at the company’s corporate office in Gachibowli, Telangana.
| Agenda Item | Description |
|---|---|
| Financial Results | Approval of results for FY ended March 31, 2026 |
| AGM Notice | Approval of notice for 33rd AGM |
| AGM Logistics | Fixing date, time, and venue for AGM |
| Scrutinizer | Appointment of scrutinizer for voting |
The disclosure was made in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Historical Stock Returns for Astal Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.08% | -1.62% | +4.11% | +4.93% | -6.81% | 0.0% |
How are analysts expecting Astal Laboratories' FY26 financial performance to compare with previous fiscal years given current market conditions?
Will the board propose any changes to dividend policy or capital allocation strategies during the upcoming AGM?
Are there any anticipated strategic shifts or new business verticals that might be highlighted in the Board Report for FY26?


































